Human Flt-3 ligand-mobilized dendritic cells require additional activation to drive effective immune responses

Experimental Hematology

Volumn 36, Issue 1, 2008, Pages 51-60

  Diener, Kerrilyn R ^a,b   Moldenhauer, Lachlan M ^a,c   Lyons, A Bruce ^a,d   Brown, Michael P ^a,e   Hayball, John D ^a,b  

^a HANSON INSTITUTE   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d FLINDERS MEDICAL CENTRE   (Australia)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; FLT3 LIGAND; FREUND ADJUVANT; OVALBUMIN; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; GENE ACTIVATION; IMMOBILIZED CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ADOPTIVE TRANSFER; AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; EGG PROTEINS; FREUND'S ADJUVANT; HUMANS; IMMUNIZATION; LYMPH NODES; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; OVALBUMIN; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; SPLEEN; T-LYMPHOCYTE SUBSETS;

MUS;

EID: 37249051881     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.08.024     Document Type: Article

References (39)

1. Kenney R.T., and Edelman R. Survey of human-use adjuvants. Expert Rev Vaccines 2 (2003) 167-188
2. Pulendran B., and Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124 (2006) 849-863
3. Janeway Jr. C.A., and Medzhitov R. Innate immune recognition. Annu Rev Immunol 20 (2002) 197-216
4. Banchereau J., Briere F., Caux C., et al. Immunobiology of dendritic cells. Annu Rev Immunol 18 (2000) 767-811
5. Shortman K., and Liu Y.J. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2 (2002) 151-161
6. Fong L., and Engleman E.G. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18 (2000) 245-273
7. Heath W.R., Belz G.T., Behrens G.M., et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 199 (2004) 9-26
8. Lyman S.D., and Jacobsen S.E.W. c-kit ligand and Flt3 ligand: stem cell/progenitor cell factors with overlapping yet distinct activities. Blood 91 (1998) 1101-1131
9. Maraskovsky E., Daro E., Roux E., et al. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 96 (2000) 878-884
10. Pulendran B., Banchereau J., Burkeholder S., et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol 165 (2000) 566-572
11. Fong L., Hou Y., Rivas A., et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumour immunotherapy. Proc Natl Acad Sci U S A 98 (2001) 8809-8814
12. Coates P.T., Barratt-Boyes S.M., Zhang L., et al. Dendritic cell subsets in blood and lymphoid tissue of rhesus monkeys and their mobilization with Flt3 ligand. Blood 102 (2003) 2513-2521
13. Maraskovsky E., Brasel K., Teepe M., et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand treated mice: multiple dendritic cell subpopulations identified. J Exp Med 184 (1996) 1953-1961
14. Sumida S.M., McKay P.F., Truitt D.M., et al. Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest 114 (2004) 1334-1342
15. Merad M., Sugie T., Engleman E.G., and Fong L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 99 (2002) 1676-1682
16. Shurin M.R., Pandharipande P.P., Zorina T.D., et al. FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol 179 (1997) 174-184
17. Lynch D.H., Andreasen A., Maraskovsky E., Whitmore J., Miller R.E., and Schuh J.C. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 3 (1997) 625-631
18. Esche C., Subbotin V.M., Maliszewski C., Lotze M.T., and Shurin M.R. FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res 58 (1998) 380-383
19. Braun S.E., Chen K., Blazar B.R., et al. Flt3 ligand antitumor activity in a murine breast cancer model: a comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action. Hum Gene Ther 10 (1999) 2141-2151
20. Viney J.L., Mowat A.M., O'Malley J.M., Williamson E., and Fanger N.A. Expanding dendritic cells in vivo enhances the induction of oral tolerance. J Immunol 190 (1998) 5815-5825
21. Yunusov M.Y., Georges G.E., Storb R., et al. FLT3 ligand promotes engraftment of allogeneic hematopoietic stem cells without significant graft-versus-host disease. Transplantation 75 (2003) 933-940
22. Berhanu A., Huang J., Alber S.M., Watkins S.C., and Storkus W.J. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy. Cancer Res 66 (2006) 4895-4903
23. Hogquist K.A., Jameson S.C., Heath W.R., Howard J.L., Bevan M.J., and Carbone F.R. T cell receptor antagonist peptides induce positive selection. Cell 76 (1994) 17-27
24. Barnden M.J., Allison J., Heath W.R., and Carbone F.R. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 76 (1998) 34-40
25. Lyons A.B., and Parish C.R. Determination of lymphocyte division by flow cytometry. J Immunol Methods 171 (1994) 131-137
26. Naik S.H., Proietto A.I., Wilson N.S., et al. Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. J Immunol 174 (2005) 6592-6597
27. Siegal F.P., Kadowaki N., Shodell M., et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 284 (1999) 1835-1837
28. Barchet W., Cella M., and Colonna M. Plasmacytoid dendritic cells-virus experts of innate immunity. Semin Immunol 17 (2005) 253-261
29. van Duin D., Medzhitov R., and Shaw A.C. Triggering TLR signaling in vaccination. Trends Immunol 27 (2006) 49-55
30. Senftleben U., Li Z.W., Baud V., and Karin M. IKKbeta is essential for protecting T cells from TNFalpha-induced apoptosis. Immunity 14 (2001) 217-230
31. Bonizzi G., and Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25 (2004) 280-288
32. Pooley J.L., Heath W.R., and Shortman K. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells. J Immunol 166 (2001) 5327-5330
33. Staerz U.D., Karasuyama H., and Garner A.M. Cytotoxic T lymphocytes against a soluble protein. Nature 329 (1987) 449-451
34. den Haan J.M., Lehar S.M., and Bevan M.J. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 192 (2000) 1685-1696
35. Hayball J.D., and Lake R.A. Partial T cell activation with an altered superantigenic ligand. Immunol Cell Biol 78 (2000) 13-19
36. Sancho D., Gomez M., and Sanchez-Madrid F. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol 26 (2005) 136-140
37. Deenick E.K., Gett A.V., and Hodgkin P.D. Stochastic model of T cell proliferation: a calculus revealing IL-2 regulation of precursor frequencies, cell cycle time, and survival. J Immunol 170 (2003) 4963-4972
38. van Stipdonk M.J., Hardenberg G., Bijker M.S., et al. Dynamic programming of CD8+ T lymphocyte responses. Nat Immunol 4 (2003) 361-365
39. den Haan J.M., and Bevan M.J. Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. J Exp Med 196 (2002) 817-827